ANAND SUBRAMANIAN: Open Payments
NPI 1316467632 · DU QUOIN, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,125 in 206 payments from 13 companies in 2025. Trend: 2023 $1,287 · 2024 $1,628 · 2025 $3,125
Food & beverage: $3,117Education: $8
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $591 |
| Otsuka America Pharmaceutical, Inc. | 29 | $422 |
| Alkermes, Inc. | 24 | $370 |
| E.R. Squibb & Sons, L.L.C. | 25 | $335 |
| Janssen Pharmaceuticals, Inc | 19 | $322 |
| Neurocrine BioSciences, Inc. | 15 | $281 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $227 |
| Teva Pharmaceuticals USA, Inc. | 23 | $196 |
| Lundbeck LLC | 8 | $137 |
| Vanda Pharmaceuticals Inc. | 6 | $96 |
Products named: VRAYLAR, REXULTI, ARISTADA, COBENFY, INGREZZA, CAPLYTA, SPRAVATO, INVEGA SUSTENNA.
Industry payments across IL — which companies pay providers there.
